BMO Capital analyst Evan Seigerman raised the firm’s price target on Incyte (INCY) to $60 from $52 but keeps an Underperform rating on the shares after its Q2 earnings beat. While the firm is encouraged by earnings, there is work to be done, the analyst tells investors in a research note. BMO adds that it “appreciates the perspective of impartiality” when assessing internal and external growth opportunities, but Incyte’s modest cash positioning could be growth-limiting for transactions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Cautious Outlook on Incyte: Sell Rating Amid Long-Term Growth Concerns and Competitive Pressures
- Incyte price target raised to $68 from $62 at UBS
- Incyte price target raised to $103 from $88 at Citi
- Incyte’s Strong Q2 2025 Results and Strategic Advances
- Incyte’s Earnings Call: Strong Growth Amid Challenges